AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23411644
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy of the neck region
Trial: 19549306
Drug: Phytotherapeutic combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytotherapeutic combination treatment
Trial: 15197195
Drug: GV (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV (gemcitabine 1000 mg/m(2) + vinorelbine 25 mg/m(2) on days 1 and 8 every 3 weeks)
Trial: 15197195
Drug: GVP (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVP (gemcitabine 1000 mg/m(2) + vinorelbine 25 mg/m(2) + cisplatin 75 mg/m(2) on day 2 every 3 weeks)
Trial: 15489869
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg/kg intravenously every 8 h
Trial: 15489869
Drug: Granisetron 10
RxNorm normalized name: GRANISETRON 10MG/0.4ML INJ,SYRINGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 10 microg/kg intravenously daily
Trial: 10077963
Drug: Low-energy extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy extracorporeal shockwave therapy (ESWT) with 250 impulses of 0.04 mJ/mm2
Trial: 10077963
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with shock-wave impact inhibited by a neopren insert
Trial: 10077963
Drug: Low-energy extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy extracorporeal shockwave therapy (ESWT)
Trial: 7235851
Drug: Treatment on
RxNorm normalized name: Canesten Clotrimazole Thrush Treatment Once (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment on a research unit
Trial: 31793165
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lixisenatide and insulin glargine
Trial: 30876869
Drug: Low-dose fascia
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fascia iliaca compartment block (FICB)
Trial: 28069051
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine plus basic treatment (steroids and 5-aminosalicylic acid)
Trial: 28069051
Drug: Azathioprine plus
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine plus basic treatment (steroids and 5-aminosalicylic acid)
Trial: 25090366
Drug: Telephone-administered supportive-expressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered supportive-expressive group therapy
Trial: 23102179
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g ground cinnamon
Trial: 19553931
Drug: PPAR-agonist treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPAR-agonist treatment
Trial: 19553931
Drug: Non-PPAR drugs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PPAR drugs
Trial: 17616069
Drug: Intravenous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment with 500 mg of sacharose ferric oxide (Venofer)
Trial: 15015147
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein restriction (0.71 g x kg(‐1) fat‐free mass x d(‐1))
Trial: 15015147
Drug: Ample American-style
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ample American-style protein intake (1.67 g x kg(‐1) fat‐free mass x d(‐1))
Trial: 9537309
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg zinc (n = 68)
Trial: 9537309
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zinc (n = 71)
Trial: 7702150
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural infusion of bupivacaine 0.2% with fentanyl 10 micrograms.ml‐1
Trial: 7702150
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural infusion of bupivacaine 0.2% with fentanyl 10 micrograms.ml‐1
Trial: 28404157
Drug: Weekly nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly nab-paclitaxel (100 mg/m2, on days 1, 8, and 15 of a 28-day cycle)
Trial: 28404157
Drug: Nab-paclitaxel every
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel every 3 weeks (260 mg/m2, on day 1 of a 21-day cycle)
Trial: 28404157
Drug: Weekly solvent-based
RxNorm normalized name: solvent yellow 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly solvent-based paclitaxel (80 mg/m2, on days 1, 8, and 15 of a 28-day cycle)
Trial: 25739878
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose measles-virus-based candidate vaccine (1.5 x 10^4 TCID50 per 0.05 mL)
Trial: 25739878
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose measles-virus-based candidate vaccine (7.5 x 10^4 TCID50 per 0.25 mL)
Trial: 25739878
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose measles-virus-based candidate vaccine (3.0 x 10^5 TCID50 per 1.0 mL)
Trial: 25739878
Drug: Measles-virus-based candidate
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles-virus-based candidate vaccine (all doses)
Trial: 17415030
Drug: MIST Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIST Therapy plus standard of wound care
Trial: 7473919
Drug: Human Growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Growth Hormone (HGH) administration
Trial: 7473919
Drug: No Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Human Growth Hormone (Control)
Trial: 31859245
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg belantamab mafodotin
Trial: 31859245
Drug: 3.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 mg/kg belantamab mafodotin
Trial: 25633544
Drug: REBT-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REBT-based intervention (8 sessions weekly: 6 individual and 2 group sessions)
Trial: 19995206
Drug: Refractive error
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refractive error and posterior capsule opacification
Trial: 11927223
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir 2000 mg four times daily for 90 days
Trial: 11927223
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 200 mg four times daily for 90 days
Trial: 9793814
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg plus droperidol 0.625 mg (Group OD)
Trial: 9793814
Drug: droperidol 0.625
RxNorm normalized name: droPERidol 0.625 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.625 mg plus metoclopramide 10 mg (Group DM)
Trial: 9793814
Drug: perphenazine 5
RxNorm normalized name: perphenazine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perphenazine 5 mg (Group P)
Trial: 8569644
Drug: Inhaled nedocromil
RxNorm normalized name: nedocromil Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nedocromil sodium 16 mg/day
Trial: 8569644
Drug: Inhaled nedocromil
RxNorm normalized name: nedocromil Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nedocromil sodium 8 mg/day
Trial: 2692894
Drug: Peripatellar methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripatellar methylprednisolone injection
Trial: 2692894
Drug: Intra-articular methylprednisolone
RxNorm normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular methylprednisolone injection
Trial: 31324040
Drug: Pectin supplementation
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin supplementation (15 g/day for four weeks)
Trial: 30672196
Drug: Heat sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat sensitive moxibustion combined with articular injection of triamcinolone, 2 courses, 2 weeks as a course, 5 times a week.
Trial: 30672196
Drug: Articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articular injection of triamcinolone, 2 courses, 2 times as a course, once every 5 days.
Trial: 22460270
Drug: Docetaxel +
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel + Sunitinib (DS arm: docetaxel 60 mg m(‐2) every 3 weeks + sunitinib 37.5 mg every day)
Trial: 22460270
Drug: Docetaxel only
RxNorm normalized name: Docetaxel only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel only (D only arm: 60 mg m(‐2), every 3 weeks)
Trial: 1694714
Drug: Flurbiprofen 150
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 150 mg + Terfenadine 180 mg
Trial: 29160135
Drug: Dienogest therapy
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest therapy (P group)
Trial: 29160135
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (C group)
Trial: 26259627
Drug: hERG potassium
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hERG potassium channel blocking drugs (Dofetilide and Moxifloxacin)
Trial: 25194614
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299 v (5 × 10(9) cfu per capsule, 2 capsules daily for 8 weeks)
Trial: 25194614
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules daily for 8 weeks)
Trial: 25194614
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L. plantarum 299 v and placebo)
Trial: 20472253
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1.5 g of n‐3 long‐chain polyunsaturated fatty acid/day)
Trial: 12909222
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of external beam radiotherapy (EBRT) and high-dose-rate intraluminal brachytherapy (ILBT) (Group 2)
Trial: 12909222
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EBRT and ILBT (Group 2)
Trial: 10318656
Drug: Eptifibatide (high-dose)
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide (high-dose)
Trial: 1776336
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PGI2 and molsidomine
Trial: 1776336
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of PGI2
Trial: 1776336
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of molsidomine
Trial: 6408274
Drug: Heparin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1000 units per liter)
Trial: 31783862
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase supplementation with triptorelin (either as a single bolus or multiple injections)
Trial: 29972000
Drug: Rehabilitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation group (routine rehabilitation treatment)
Trial: 26932144
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline administered intravenously)
Trial: 20846441
Drug: Weekly 30-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 30-minute massage sessions
Trial: 20846441
Drug: Massages plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massages plus stretching exercises performed twice a day
Trial: 9243352
Drug: Oral selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selegiline (10 mg)
Trial: 12077684
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PGl 2 and aprotinin
Trial: 8749880
Drug: Disopyramide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (2 mg/kg)
Trial: 2522723
Drug: Celiprolol (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200, 400, 600 mg/day)
Trial: 30900658
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac sodium (100 mg twice daily)
Trial: 27993667
Drug: Convective radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convective radiofrequency thermal therapy with the Rezūm® System
Trial: 27993667
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rigid cystoscopy with simulated active treatment)
Trial: 22807253
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + prednisone (10 mg of prednisone)
Trial: 12932067
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with hyperbaric bupivacaine 0.5% 5 mg and fentanyl 25 microg
Trial: 10720278
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of NGF
Trial: 7886781
Drug: IVR 400
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVR 400 micrograms/kg plus DEC 6 mg/kg
Trial: 30829679
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of lactoferrin and 0.2 g of lysozyme daily for 16 weeks
Trial: 24294684
Drug: Specially processed
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specially processed cereal (SPC) treatment
Trial: 21683053
Drug: Audio feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio feedback with cognitive preparation
Trial: 15552536
Drug: Carbamazepine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (600 mg/day) added to fluphenazine (5-10 mg/day)
Trial: 15552536
Drug: Sole fluphenazine
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sole fluphenazine (5-10 mg/day)
Trial: 9089819
Drug: No antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antipsychotic medications
Trial: 1447391
Drug: Metronidazole 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 25% dental gel administered 1 x a week for 2 weeks
Trial: 1447391
Drug: Metronidazole 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 15% dental gel applied 1 x a week for 2 weeks
Trial: 1447391
Drug: Metronidazole 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 15% dental gel applied 2 x a week for 2 weeks
Trial: 17910618
Drug: Indinavir combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir combined with low-dose ritonavir
Trial: 17910618
Drug: Saquinavir combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir combined with low-dose ritonavir
Trial: 17910618
Drug: Lopinavir combined
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir combined with low-dose ritonavir
Trial: 15616073
Drug: Ketamine 10
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 10 mg
Trial: 12391054
Drug: Naloxone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (30 mg iv bolus)
Trial: 1789399
Drug: Budesonide powder
RxNorm normalized name: budesonide Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide powder 400 micrograms daily
Trial: 1789399
Drug: Budesonide powder
RxNorm normalized name: budesonide Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide powder 800 micrograms daily
Trial: 1789399
Drug: Budesonide aerosol
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aerosol 400 micrograms daily
Trial: 28912191
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy administration (30 kcal/kg/day) starting within 24 hours of hospital admission
Trial: 28912191
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy administration during the first 72 hours of hospital admission
Trial: 21541815
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (38 diabetic patients on medical therapy)
Trial: 18807128
Drug: omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 10 mg and 20 mg
Trial: 11870241
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (400 mg oral daily)
Trial: 2533450
Drug: High-dose MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MPA (100 mg/day)
Trial: 2533450
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (Danazol and MPA)
Trial: 19508712
Drug: Web-based self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based self-management programme for insulin titration
Trial: 15365700
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HRT)
Trial: 11875727
Drug: ALT (Docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALT (Docetaxel 100 mg/m² plus FEC 75) alternated for eight courses
Trial: 11875727
Drug: SEQ T
RxNorm normalized name: Selegiline
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SEQ T (Four courses of Docetaxel 100 mg/m² followed by four courses of FEC 75)
Trial: 11875727
Drug: SEQ F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEQ F (Four courses of FEC 75 followed by four courses of Docetaxel 100 mg/m²)
Trial: 10086937
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Synacthen test (LDST)
Trial: 2193496
Drug: Lidoflazine 360
RxNorm normalized name: Lidoflazine
DrugBank: Lidoflazine (DB13766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidoflazine 360 mg daily
Trial: 30959528
Drug: Group Treatment
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Treatment (GT)
Trial: 30959528
Drug: Self-Administered Individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Administered Individual Treatment (SIT)
Trial: 22782464
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic antibiotic administration
Trial: 22782464
Drug: Extended prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended prophylactic antibiotic administration
Trial: 17531921
Drug: Augmentation Index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation Index (AI)
Trial: 15087948
Drug: Native Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native Escherichia coli asparaginase (9 doses during induction)
Trial: 15087948
Drug: PEG-asparaginase (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-asparaginase (6 or 10 doses)